PISA, Italy--(BUSINESS WIRE)--July 5, 2006--Abiogen Pharma today announced the start of a Phase II clinical trial in Vienna (Austria) in patients affected by GAD with ABIO 08/01, a new anti-anxiety drug. ABIO 08/01 is the first in a new class of non-addictive drugs, different from anxiolytic sedatives, and is being developed to treat clinical anxiety states such as panic disorder or GAD.